分类 默认分类 下的文章

Rybelsus.webp
A diabetes treatment drug called "Semaglutide" is rapidly gaining popularity due to its excellent weight loss results. Even Tesla CEO Elon Musk is full of praise for it, once revealing that the secret to losing 9 kilograms in a month is to fast and take semaglutide regularly.
Semaglutide Growth Trajectory:
In December 2017, the U.S. Food and Drug Administration (FDA) officially approved semaglutide injection for blood sugar control in adults with type 2 diabetes.
In September 2019, the US FDA approved Rybelsus (oral semaglutide) for medical use.
In January 2020, the FDA granted its new use approval again to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes mellitus with cardiovascular disease. In December of the same year, Novo Nordisk submitted a marketing application to the FDA for semaglutide 2.4mg subcutaneously once a week for weight loss.
In April 2021, the State Food and Drug Administration (NMPA) also approved its use in China for the treatment of type 2 diabetes in adults and to reduce the risk of cardiovascular adverse events in patients with T2DM and cardiovascular disease.
In June 2021, the FDA further approved it for the treatment of obesity, allowing semaglutide (Wegovy) injection to be used in adult obese individuals with a BMI of ≥30 or adults with a BMI of ≥27 with at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia. Studies have shown that obese patients treated with semaglutide lose an average of 17%-18% of their weight over 68 weeks.
In January 2023, the FDA approved a new indication for Wegovy (semaglutide injection) for chronic weight management in pediatric patients with an age- and sex-adjusted initial body mass index (BMI) of 95% or more, 12 years of age and older, as an adjunct to low-calorie diets and increased physical activity. This is one of the few drugs in the world that is currently officially approved by the FDA for the treatment of obesity.
Oral semaglutide is highly regarded as the high-profile drug of the year. The following is a summary of several questions about semaglutide that everyone is most concerned about for reference.

- 阅读剩余部分 -